DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022

Rhea-AI Summary

DBV Technologies will report its full year 2021 financial results on March 3, 2022. The company, based in Montrouge, France, is focused on developing the Viaskin platform for immunotherapy, specifically for food allergies. A conference call will be held at 5:00 p.m. ET to discuss the financial outcomes and provide corporate updates. The call can be accessed via specified teleconferencing numbers and a live audio webcast will be available on their website.

Positive

• Scheduled conference call for financial results indicates transparency.
• Focus on Viaskin platform for immunotherapy shows potential growth in food allergy treatments.

Negative

• None.

Montrouge, France, February 24, 2022

DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, March 3, 2022 at 5:00 p.m. ET to report full year 2021 financial results and provide a corporate update.

This call is accessible via the below teleconferencing numbers, followed by the reference ID: 50283860.
United States: (866) 939-3921                                                
Canada: (866) 215-5508
United Kingdom: 0808 238 9578                                        
France: 0805 102 604

A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies 
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com 

 

Attachment

• PDF Version

FAQ

When will DBV Technologies report its 2021 financial results?

DBV Technologies will report its 2021 financial results on March 3, 2022.

What time is the DBV Technologies conference call?

The DBV Technologies conference call is scheduled for 5:00 p.m. ET.

How can I access the DBV Technologies conference call?

You can access the DBV Technologies conference call via designated teleconferencing numbers or live audio webcast on their website.

What is the focus of DBV Technologies?

DBV Technologies is focused on developing the Viaskin platform for immunotherapy, particularly for food allergies.